Skip to main content

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment.

After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23.

The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector.

In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down.

The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore.

Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal.

Light at the end of the tunnel

Titan can get benefits from the strong market share in the jewellery and wrist watches segment mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment.

Brokerages highlight Titan has major revenue and EBIDTA comes from the jewellery segment which is highly sensitive to the overall macro-economic scenario. The company also benefits out of a large share of franchisee sales which helps more in the current times of underutilization.

Reports indicate Tanishq revenues have recovered to 90 percent of pre-COVID levels – significantly ahead of consensus expectations.

Brokerage firm ICICI Securities has upgraded the stock to 'add' from 'hold', with a DCF-based revised target price of Rs 1,250 from Rs 1,100 earlier.

The brokerage has increased FY22 earnings estimates by nearly 2 percent and modelled revenue, EBITDA and PAT CAGR of 14, 13 and 16 percent, respectively over FY20-22E.


"A


s Tanishq revenues have recovered significantly ahead of consensus expectations, likely drivers of this trend are (1) boost to volumes due to (somewhat) stable gold prices, (2) consumers have (likely) started accepting higher gold prices and expect further inflation and (3) market share gains (liquidity challenges for smaller competitors)," ICICI Securities said.

"Upside trigger is gold price correction or volatility leading to a surge in volumes. That said, the introduction of fixed making charges, even though a small proportion currently, is something that we will watch carefully," the brokerage added.

Brokerage firm HDFC Securities has a buy call on the stock with a base case fair value of Rs 1,192 and a bull case fair value of Rs 1,266 for six months.

HDFC Securities is of the view that the Indian retail industry is likely to go through a strong consolidation phase which is likely to benefit companies of the likes of Titan mainly due to its robust balance sheet and

phenomenal track record of consistent market share gains.

The brokerage added that the management continued focus on new launches and consistent expansion of the product portfolio by entering into newer categories is further likely to fuel future growth.

The brokerage expects that COVID-19 led lockdown and slowdown in the economy will lead to subdued growth and sluggish operational performance in FY21.

"Titan is a structural growth story and is a strong play on the consumption theme and rides on the long-term opportunity on rising income, increased discretionary spending, gains from penetration and premiumisation trends," HDFC Securities said.

Disclaimer: The views and investment tips expressed by investment experts on SD Solutions are their own and not that of the website or its management. SD Solutions advises users to check with certified experts before taking any investment decisions.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...